A phase I/II trial of 2-deoxyglucose (2DG) for the treatment of advanced cancer and hormone refractory prostate cancer.

Trial Profile

A phase I/II trial of 2-deoxyglucose (2DG) for the treatment of advanced cancer and hormone refractory prostate cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2014

At a glance

  • Drugs 2-deoxy-D-glucose (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2011 Planned End Date changed from 1 Apr 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top